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Fatty acid synthase (FASN), the sole cytosolic mammalian enzyme
for de novo lipid synthesis, is crucial for cancer cell survival and
associates with poor prognosis. FASN overexpression has been
found to cause resistance to genotoxic insults. Here we tested the
hypothesis that FASN regulates DNA repair to facilitate survival
against genotoxic insults and found that FASN suppresses NF-κB
but increases specificity protein 1 (SP1) expression. NF-κB and SP1
bind to a composite element in the poly(ADP-ribose) polymerase 1
(PARP-1) promoter in a mutually exclusive manner and regulate
PARP-1 expression. Up-regulation of PARP-1 by FASN in turn in-
creases Ku protein recruitment and DNA repair. Furthermore, lipid
deprivation suppresses SP1 expression, which is able to be rescued
by palmitate supplementation. However, lipid deprivation or pal-
mitate supplementation has no effect on NF-κB expression. Thus,
FASN may regulate NF-κB and SP1 expression using different
mechanisms. Altogether, we conclude that FASN regulates cellular
response against genotoxic insults by up-regulating PARP-1 and
DNA repair via NF-κB and SP1.
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Fatty acid synthase (FASN) is the key mammalian enzymerequired for de novo synthesis of palmitate. FASN expression
and activity are largely suppressed by sufficient dietary fat in
most normal nonadipose tissues but are abnormally elevated in
many human cancers and associated with poor prognosis (1).
FASN association with poor prognosis may derive in part from
FASN function in drug resistance during chemotherapy. Indeed,
it has been found that FASN expression and/or activity was in-
creased in drug-selected and -resistant breast (2) and pancreatic
(3) cancer cells. It was also found that FASN overexpression
causes cellular resistance to DNA-damaging drugs such as
doxorubicin and mitoxantrone but not to microtubule modula-
tors such as vinblastine and paclitaxel (4). Decreased ceramide
production following doxorubicin treatment via suppression of
tumor necrosis factor (TNF)-α production is believed to be one
of the mechanisms of FASN-induced resistance to doxorubicin (4).
The observation that FASN increases resistance to genotoxic
drugs prompted us to hypothesize that FASN overexpression
may up-regulate DNA damage response/repair pathways. In this
study, we tested this hypothesis with a focus on the repair of
DNA double-strand breaks (DSBs), which are commonly induced
by the anticancer drugs doxorubicin and mitoxantrone and ionizing
radiation. In mammalian cells, DSBs are repaired mainly via ho-
mologous recombination (HR) and nonhomologous end-joining
(NHEJ) pathways. NHEJ is the predominant form of DSB re-
pair because it occurs during all phases of the cell cycle whereas
HR only initiates at late G1 and S phases (5). Hence, we examined
NHEJ repair of DSBs and found that FASN up-regulates NHEJ
activity and repair of DSBs by increasing poly(ADP-ribose) po-
lymerase 1 (PARP-1) expression via increasing the expression of
specificity protein 1 (SP1) and reducing the expression of NF-κB,
which bind to the same composite element in the PARP-1 pro-
moter. Furthermore, lipid deprivation suppresses SP1 expres-
sion, which is able to be rescued by palmitate supplementation.
With these findings, we conclude that FASN may up-regulate
DNA repair mechanisms by increasing PARP-1 expression via
NF-κB and SP1, which in turn contributes to cellular resistance
to genotoxic anticancer treatments. Thus, lipid metabolism likely
plays an important role in cancer cell survival against genotoxic
insults by regulating DNA repair pathways.
Results
FASN Overexpression Causes Resistance to Multiple Genotoxic Treatments.
We previously reported that FASN overexpression increases cellular
resistance to anticancer drugs that cause DSBs but not to non–DNA-
damaging drugs (2, 4). To determine whether FASN overexpression
causes resistance to genotoxic treatments that cause different types of
DNA lesions, we tested the survival of a previously established stable
MCF7 clone with FASN overexpression (M/FASN) in comparison
with vector-transfected (M/Vec) control cells (4) (see also Fig. 1A)
following treatments with bleomycin, cisplatin, doxorubicin, H2O2,
ionizing radiation (IR), and UVB. As shown in Fig. 1B and Fig. S1A,
M/FASN cells are significantly more resistant to all these treatments
than M/Vec cells. Stable FASN knockdown (M3K/Sh) in a drug-
resistant MCF7/AdVp3000 cell line (Fig. 1A), which has elevated
endogenous FASN levels compared with the parental MCF7 cells (4),
significantly reduced resistance levels to these treatments compared
with the control cells (M3K/Scr) (Fig. 1B and Fig. S1B). Thus, FASN
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overexpression likely contributes to cellular resistance to multiple
genotoxic treatments that cause different types of DNA lesions.
FASN Overexpression Increases Repair of IR- and Doxorubicin-Induced
DNA Damage. The above findings suggest that FASN overex-
pression may protect cells against DNA damage induced by these
genotoxic treatments or by increasing the repair of this damage.
To test this possibility, we focused on DSBs induced by IR for
the convenience of monitoring repair and because DSBs appear
to be mostly affected by FASN (Fig. 1B). We first performed a
neutral comet assay with the two paired cell lines (M/FASN vs.
M/Vec and M3K/Sh vs. M3K/Scr) following IR treatment. Fig.
2A shows that, at 1 h following IR treatment, the reported time
of maximal DNA damage induction post IR exposure (6), both
M/FASN and M/Vec cells formed similarly elongated tails with
no difference in olive tail moment, indicating that the DNA in
both cells is equally damaged by IR and that FASN overex-
pression may not protect cells from IR-induced DNA damage.
Similar results were also observed for M3K/Sh and M3K/Scr cells
(Fig. 2B). However, at 4 h after IR, a dramatic difference in olive
tail moment was observed between M/FASN and M/Vec cells
and between M3K/Sh and M3K/Scr cells. Whereas the olive tail
moment was significantly lower in M/FASN cells, it was signifi-
cantly higher in M3K/Sh cells than their respective control cells.
These findings indicate that FASN may increase the cellular
repair activity of DSBs induced by IR.
To verify the above findings, we next determined the level of
γ-histone 2AX (γ-H2AX), an indicator of DSBs (7), in these
paired cells at different recovery times following IR by Western
blot analysis. As shown in Fig. 3 A and B, a similarly induced
level of γ-H2AX was detected between M/FASN and M/Vec
cells and between M3K/Sh and M3K/Scr cells at 1 h following IR
compared with their respective untreated control cells. However,
γ-H2AX levels decreased significantly more in M/FASN than
M/Vec control cells and decreased significantly less in M3K/Sh
than M3K/Scr control cells at 4 h following IR. These observations
are consistent with the findings of the comet assay (Fig. 2). Immu-
nofluorescence analysis of M3K/Sh and M3K/Scr cells showed
equivalent increases in punctate staining of γ-H2AX in the nuclei
of both cells at 1 h after IR compared with the control untreated
cells (Fig. 3D). At 4 h after IR, the nuclear staining of γ-H2AX in
M3K/Scr control cells reduced dramatically whereas it remained
at high levels in M3K/Sh cells with FASN depleted. These ob-
servations are consistent with that shown by Western blot analysis
of γ-H2AX expression.
Because M3K/Scr vs. M3K/Sh and M/Vec vs. M/FASN cells in
the above studies are of the same MCF7 origin, the above ob-
servations may be specific to MCF7 cells. To eliminate this
possibility, we tested another pair of cell lines of different genetic
background, P/FASN (with ectopic FASN overexpression) and
P/Vec (vector-transfected control), both derived from Panc-1
cells (8) (Fig. 3C). Whereas the γ-H2AX level was similarly high
between P/FASN and P/Vec cells at 1 h following IR treatment,
it was significantly reduced in P/FASN cells compared with
P/Vec cells at 4 h following IR treatment (Fig. 3C). This finding
was confirmed by the punctate staining of γ-H2AX in the nuclei of
P/FASN and P/Vec cells (Fig. 3D). Thus, the function of FASN in
promoting DSB repair may not be cell line-specific.
Because FASN overexpression contributes to cellular resistance
to the anticancer drug doxorubicin (Fig. 1), which also induces
DSBs, we next determined whether FASN overexpression has a
similar effect on γ-H2AX due to DSBs induced by doxorubicin. As
shown in Fig. S2A, at 4 h of treatment, γ-H2AX reached maxi-
mum levels in both M/FASN and control M/Vec cells. At 6 h and
beyond, M/FASN cells have less γ-H2AX than the control M/Vec
cells. This observation was also corroborated by immunostaining
of γ-H2AX in the nuclei shown in Fig. S2B. Together, these
findings suggest that higher FASN expression levels may increase
the repair of IR- or doxorubicin-induced DSBs.
Fig. 1. Effect of FASN on the cellular response to genotoxic treatments. (A) Western blot analysis of FASN expression in stable MCF7 cells with FASN over-
expression (M/FASN), MCF7/AdVp3000 cells with stable FASN knockdown (M3K/Sh), and their respective control vector-transfected (M/Vec) and scrambled control
shRNA-transfected (M3K/Scr) cells. (B) Survival assay. M/FASN, M3K/Sh, and their respective control cells were tested for resistance to bleomycin (BLEO), cisplatin
(CDDP), doxorubicin (DOX), and H2O2 using an MTT assay, and to ionizing radiation and UVB using a colony-formation assay (n = 3; *P < 0.05, **P < 0.01; error
bars, standard deviation).
Fig. 2. Effect of FASN on the accumulation of IR-induced DNA damage.
Stable FASN-overexpressing (M/FASN) and control (M/Vec) cells (A) as well as
stable FASN knockdown (M3K/Sh) and control (M3K/Scr) cells (B) were
treated with or without 5 Gy IR and then subjected to a neutral comet assay
at different times. The histograms show quantitative olive moment analysis
from three independent experiments (*P < 0.05, **P < 0.01; error bars,
standard deviation).
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FASN Overexpression Increases NHEJ Repair Activity.Next, we tested
the possibility that FASN overexpression increases the repair of
DSBs using a reporter-based host cell reactivation assay of both
NHEJ and HR activities without drug or IR treatments. As shown
in Fig. 3E, M3K/Sh cells with FASN knockdown had significantly
reduced NHEJ activity than control M3K/Scr cells whereas P/FASN
cells with FASN overexpression had significantly increased NHEJ
activity over control P/Vec cells. However, HR activity was signifi-
cantly increased and reduced, respectively, in M3K/Sh and P/FASN
cells compared with their control cells (Fig. S3). These findings are
very interesting and suggest that NHEJ but not HR may contribute
to FASN-induced resistance to IR (Discussion).
FASN Overexpression Enhances Ku Protein Recruitment and DNA-PK
Activity. We next investigated the molecular basis of the up-regu-
lated NHEJ activity by FASN overexpression. Because NHEJ
repair is initiated by recruiting Ku70/80 dimers and DNA-PKcs
to the damage sites and because increased Ku70 expression has
been found to promote cellular resistance to doxorubicin and
ionizing radiation (9–11), we tested the effect of FASN on
Ku70 expression and recruitment to damaged chromatin. As
shown in Fig. 4 A and B, M3K/Sh cells with FASN knockdown
and P/FASN cells with FASN overexpression had similar total
and cytoplasmic Ku70 levels as their respective control cells
before and after IR. The chromatin-bound Ku70 was increased
in all cells following IR treatment. However, the increase was
greater in P/FASN cells and less in M3K/Sh cells compared
with their respective control cells. These changes were ac-
companied by the corresponding lower and higher levels of
Ku70 in the unbound (soluble) nuclear fractions than their
respective controls. Further, more chromatin-bound Ku70
protein in P/FASN and less in M3K/Sh cells was accompanied
Fig. 3. Effect of FASN on DSB repair. (A–C) Western blot analysis of IR-induced γ-H2AX in FASN-overexpressing MCF7 (M/FASN) and its control (M/Vec) cells
(A), stable FASN knockdownMCF7/AdVp3000 (M3K/Sh) and its control (M3K/Scr) cells (B), and FASN-overexpressing Panc-1 (P/FASN) and its control (P/Vec) cells
(C ). Histograms show relative γ-H2AX levels determined from three independent experiments. (D) Immunofluorescence staining of γ-H2AX in M3K/Sh,
P/FASN, and their respective control M3K/Scr and P/Vec cells. DNA was stained by DAPI. (E ) NHEJ activity assay. M3K/Sh and P/FASN cells along with
their respective control M3K/Scr and P/Vec cells were subjected to an NHEJ host cell reactivation assay as described in Experimental Procedures (n = 4; *P < 0.05,
**P < 0.01; error bars, standard deviation). F, FASN; Vec, vector.
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by significantly augmented and reduced DNA-PK activity follow-
ing IR compared with their respective controls (Fig. 4C). Thus, we
conclude that FASN overexpression increases recruitment of Ku
proteins to chromatin and DNA-PK activity following IR-induced
DNA damage.
It is noteworthy that Ku70 binding to chromatin and DNA-PK
activity were sustained at 4 h post IR, when most DNA damage
was repaired, as evidenced by the significant decrease in γ-H2AX
level/foci and reduction in olive tail moment (Figs. 2 and 3). It is
possible that the sustained Ku70 retention on chromatin was due
to the existence of residual DNA damage at 4 h post IR, as also
indicated by γ-H2AX level/foci and olive tail moment (Figs. 2 A
and B and 3 A–C). To test this possibility, we analyzed chro-
matin-bound Ku70 at 8 h post IR. As shown in Fig. S4, the
chromatin-bound Ku70 was reduced to the basal level. Thus, the
sustained chromatin retention of Ku70 and DNA-PK activity
may be due to cellular activity to repair residual DNA damage.
FASN Overexpression Promotes PARP-1 Expression, Which Mediates FASN
Enhancement of NHEJ Repair and Cellular Resistance to IR. PARP-1 has
emerged as a key player in the DSB repair pathway (12, 13) and was
found to promote recruitment and retention of Ku at DSB sites via
Ku70 binding to poly(ADP-ribosyl)ated (PARylated) nuclear pro-
teins and facilitate NHEJ repair (14). Thus, we tested the possibility
that FASN overexpression up-regulates PARP-1 expression, which
in turn promotes Ku70 recruitment and increases NHEJ activity.
Fig. 5A shows that PARP-1 protein is increased dramatically in
M/FASN and P/FASN clones with FASN overexpression but is de-
creased in the stable M3K/Sh clone with FASN knockdown com-
pared with their respective control cells. PARP-1 mRNA also
changed similar to PARP-1 protein in these cells (Fig. 5B).
We next examined whether increased PARP-1 expression due
to FASN overexpression would lead to higher PARP activity
following DNA damage by determining PARylated histone H3, a
target of PARP-1 after DNA damage and relevant to DNA re-
pair (15). For this purpose, the stable P/FASN clone and its
P/Vec control cells were treated without or with 5 Gy IR, followed
by immunoprecipitation of histone H3 and Western blot analysis
of PARylated histone H3. As shown in Fig. 5C, PARylated
histone H3 was increased in P/FASN cells compared with the
control P/Vec cells following IR. Pretreatment with the
PARP-1 inhibitor olaparib inhibited IR-induced PARylation
with minimal remaining PARylation of histone H3 (Fig. 5C).
Clearly, the increased PARP-1 expression is accompanied by
increased PARP-1 activity.
To determine whether the increased PARP-1 mediates FASN
enhancement of NHEJ activity, we transiently transfected
P/FASN cells with PARP-1 siRNA to knock down PARP-1 ex-
pression followed by an NHEJ activity assay. Fig. 5D shows that
the increased PARP-1 level in P/FASN cells due to FASN over-
expression is successfully suppressed by PARP-1 siRNA. The in-
creased NHEJ activity due to FASN overexpression in P/FASN
cells is significantly reduced by PARP-1 knockdown. Together,
these findings suggest that FASN up-regulates PARP-1 expres-
sion, which in turn increases NHEJ activity, possibly by promoting
Ku recruitment and enhancing DNA-PK activity.
To determine whether FASN enhancement of PARP-1 likely
mediates FASN function in cellular resistance to DNA damage,
we performed a survival assay of P/FASN cells following doxo-
rubicin treatment in the absence or presence of the PARP-1
inhibitors 3-ABA (3-aminobenzamide) and olaparib. As shown
in Fig. 5E, either 1 mM 3-ABA or 0.5 μM olaparib alone had no
effect on M/FASN cell survival. However, 1 mM 3-ABA and
0.5 μM olaparib significantly reduced the doxorubicin resistance
level of M/FASN cells (Fig. 5F and Fig. S5). Similarly, knocking
down PARP-1 using siRNA also significantly sensitized M/FASN
cells to doxorubicin (Fig. 5F). These findings suggest that PARP-1
likely mediates FASN overexpression-induced resistance to DSBs,
possibly by increasing NHEJ repair of DSBs.
Both MCF7 and Panc-1 cells are known to express high levels
of endogenous FASN, and M3K cells have further elevated en-
dogenous FASN (2, 8, 16). To eliminate the possibility that the
above observations may be due to forced increases in FASN
expression either by ectopic transfection or drug selection, we
transiently knocked down FASN in the parental MCF7 cells and
tested its effect on doxorubicin sensitivity, NHEJ activity, and
PARP-1 expression. As shown in Fig. S6, FASN knockdown in
MCF7 cells significantly reduced doxorubicin resistance, NHEJ
activity, and PARP-1 expression. These findings are consistent
with our previous observation that FASN knockdown in MDA-
MB-468 cells also significantly reduced doxorubicin and mitox-
antrone resistance (2). Thus, endogenous levels of FASN in
cancer cells likely regulate cellular response to DNA damage and
NHEJ repair of DSBs.
FASN Transcriptionally Regulates PARP-1 Expression Through Inhibition
of NF-κB and Up-Regulation of SP1. Fig. 5B shows that the mRNA
level of PARP-1 was increased by FASN overexpression and de-
creased by FASN knockdown, suggesting that FASNmay participate
Fig. 4. Effect of FASN on Ku recruitment and DNA-PK activity. (A and B)
Western blot analysis of Ku70 distribution in different cellular fractions
following IR in FASN-overexpressing Panc-1 cells (P/FASN) (A), FASN knock-
down MCF7/AdVp3000 cells (M3K/Sh) (B), and their respective control cells
(P/Vec and M3K/Scr). Tubulin, actin, and histone H3 were used as markers for
cytosolic, soluble nuclear, and insoluble chromatin fractions, respectively.
(C) DNA-PK activity assay. P/FASN and M3K/Sh cells together with their re-
spective control P/Vec and M3K/Scr cells were treated without or with IR and
harvested at the indicated times following IR for determination of DNA-PK
activity (n = 3; *P < 0.05, **P < 0.01; error bars, standard deviation).
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in regulating PARP-1 transcription. To understand how FASN
promotes PARP-1 transcription, we examined the promoter se-
quence of human PARP-1 and found a composite element with
overlapping binding sites for NF-κB and SP1 transcription factors
(Fig. 6A). Previously, it has been shown that the rat PARP-1 gene
is activated by SP1 (17) and inactivated by NF1, which competes
with SP1 on a composite element in the promoter of rat PARP-1
(18). We have also shown that FASN down-regulates NF-κB ex-
pression (4). Fig. 6B shows that FASN overexpression in Panc-1
cells and knockdown in MCF7/AdVp3000 (M3K) cells also sig-
nificantly decreased and increased, respectively, p65 expression as
determined using Western blot and NF-κB activity using a re-
porter assay. On the other hand, FASN overexpression increased
SP1 expression whereas FASN knockdown reduced SP1 expres-
sion (Fig. 6C). We also tested whether the effect of FASN on SP1
and NF-κB expression is possibly via its catalytic product palmitate
by culturing cells in delipidated serum with or without palmitate
supplementation. As shown in Fig. 6D, culturing Panc-1 cells in
media with delipidated serum reduced the expression of SP1 and
PARP-1 but not NF-κB. Supplementation of palmitate rescued
both SP1 and PARP-1 expression from the suppression. However,
altering the cell cycle in P/FASN cells had no effect on PARP-1
expression (Fig. 6E). Thus, palmitate may play an important role
in mediating FASN regulation of SP1 expression but not NF-κB.
Based on the above studies, we hypothesized that FASN
promotes PARP-1 expression by suppressing NF-κB and in-
creasing SP1, which bind to the PARP-1 promoter in a mutually
exclusive manner. To test this hypothesis, we first determined
whether SP1 and NF-κB regulate PARP-1 expression by tran-
siently transfecting MCF7 and Panc-1 cells with SP1 or p65 cDNA
followed by determination of their effect on the expression of
endogenous PARP-1. As shown in Fig. 7A, SP1 overexpression
dramatically increased whereas Flag-p65 overexpression signifi-
cantly reduced PARP-1 protein and mRNA levels. Knocking down
p65 using shRNA significantly increased PARP-1 protein and
mRNA levels (Fig. 7B), whereas activation of p65 with TNF-α had
the contrary effect (Fig. 7C). Taken together, these results suggest
that NF-κB and SP1 oppose each other in regulating PARP-1
transcription, with NF-κB functioning as a suppressor and SP1 as
an activator.
To determine whether NF-κB interferes with SP1 activation
of PARP-1 expression and vice versa, we cotransfected varying
amounts of Flag-p65 and SP1 cDNAs into Panc-1 cells followed by
determination of PARP-1 expression. As shown in Fig. 7D, SP1
expression increased PARP-1 protein levels (compare lanes 1 and 2).
However, an SP1-induced increase in PARP-1 protein level was
Fig. 5. PARP-1 mediates FASN-associated DNA repair and genotoxic treatment resistance. (A and B) Effect of FASN on PARP-1 expression as determined by
Western blot (A) and real-time RT-PCR (B) in stable FASN-overexpressing and knockdown cells. (C) Effect of FASN on IR-induced histone H3 PARylation. Cells
were pretreated without or with 0.5 μM olaparib followed by treatment with or without IR and harvested at different times following IR for lysate prep-
aration, immunoprecipitation (IP) of histone H3 in the presence of 100 μM poly(ADP-ribose) glycohydrolase inhibitor gallotannin, and Western blot analysis
(IB) of PARylated and total histone H3. (D) Effect of PARP-1 knockdown on FASN-induced NHEJ up-regulation. FASN-overexpressing (P/FASN) and control
(P/Vec) cells were transiently transfected with PARP-1 or scrambled control siRNA followed by Western blot analysis of PARP-1 (Left) and NHEJ activity assay
(Right). (E) Effect of PARP-1 inhibition on survival. M/FASN cells were treated with 1 mM 3-ABA, 0.5 μM olaparib, or their vehicle control for 48 h followed by
an MTT assay. (F) Effect of PARP-1 inhibition on doxorubicin resistance. M/FASN cells were pretreated for 6 h by 1 mM 3-ABA or 0.5 μM olaparib or transfected
with control or PARP-1 siRNA followed by testing doxorubicin resistance using an MTT survival assay (n = 3–4; *P < 0.05, **P < 0.01; error bars, standard
deviation).
Fig. 6. Effect of FASN on p65 and SP1 expression. (A) Putative composite
element in the human PARP-1 proximal promoter. The overlapping under-
lined sequences represent NF-κB– and SP1-binding sites. The numbers indicate
positions relative to the transcription start site (arrow). (B) Effect of FASN
overexpression in Panc-1 cells or knockdown in MCF7/AdVp3000 cells on p65
expression and NF-κB activity. (C) Effect of FASN overexpression in Panc-1 cells
or knockdown in MCF7/AdVp3000 cells on SP1 expression. (D) Effect of deli-
pidation (DL) and palmitate supplementation (Pal) culture on SP1 and p65
expression in Panc-1 cells. (E) Effect of cell-cycle distribution on PARP-1 ex-
pression as determined using real-time RT-PCR. Different cell-cycle stages were
achieved by culturing P/FASN cells in serum-free (S.F.) media for G0/G1, thy-
midine (Thy.) block for S, and nocodazole (Noc.) treatment for G2/M phases
(n = 3; *P < 0.01; error bars, standard deviation).
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diminished by p65 cDNA in a dose-dependent manner (compare
lanes 2, 3, and 4, Fig. 7D). On the other hand, when p65 cDNA
was kept constant, increasing SP1 cDNA from 0 to 2 μg resulted in
a steady increase in PARP-1 level (compare lanes 5, 3, and 6).
To further determine whether NF-κB interferes with SP1
binding to and activation of the PARP-1 promoter, we performed
a chromatin immunoprecipitation (ChIP) assay to quantify SP1-
bound PARP-1 promoter following ectopic p65 overexpression in
Panc-1 cells. As shown in Fig. 7E, the PARP-1 promoter immu-
noprecipitated by SP1 antibody was reduced significantly from
∼13% (relative to input) in vector-transfected control cells to ∼7%
in p65-overexpressing cells. Collectively, these results suggest that
NF-κB likely interferes with SP1 binding to and activation of
the PARP-1 promoter for PARP-1 expression, possibly via
competition for binding onto the composite element within the
PARP-1 promoter.
Finally, to determine whether these transcription factors pos-
sibly play any role in up-regulating NHEJ activity, we analyzed the
effect of p65 knockdown on NHEJ activity. As shown in Fig. 7F,
p65 shRNA effectively knocked down p65 expression, which led to
a significant increase in NHEJ activity in MCF7 cells. This finding
suggests that downregulating NF-κB expression by FASN may
contribute to the increased NHEJ repair of DSBs.
Discussion
Accumulating evidence shows that FASN expression is up-reg-
ulated in human cancers and provides survival advantages for
cancer cells. FASN overexpression has also been associated with
resistance to anticancer treatments (1). However, the molecular
mechanisms of FASN function in drug resistance are largely
unknown. In the present study, we show that FASN overex-
pression suppresses NF-κB whereas up-regulates SP1, which in
turn increases PARP-1 expression and facilitates recruitment of
Ku proteins to IR- or drug-induced DSBs for NHEJ repair. This
cascade of events results in resistance to treatments, including IR
and doxorubicin, that elicit DSBs (Fig. S7).
In addition to IR, doxorubicin, and bleomycin, which all cause
DSBs, we also found that FASN overexpression contributes to
resistance to cisplatin, H2O2, and UVB, which primarily cause
other types of DNA lesions repaired by the nucleotide excision
repair (NER) and base excision repair (BER) pathways. Because
PARP-1 is known to play important roles in both the BER and
NER pathways (19–22), FASN may also contribute to resistance
to cisplatin, H2O2, and UVB by up-regulating NER and BER
activities via increasing PARP-1 expression and activity. In line
with our findings, overexpression and constitutive hyperactivation
of PARP-1 have been associated with cisplatin resistance in non–
small-cell lung cancer (23).
As a nuclear enzyme, PARP-1 is activated by DNA damage.
Activated PARP-1 posttranslationally modifies many nuclear
proteins such as histones and DNA repair proteins by adding
ADP-ribose polymers onto lysine residues, a process termed poly
(ADP-ribosyl)ation (15), and has been implicated in playing
important roles in different DNA repair pathways (24, 25). For
NHEJ repair of DSBs, PARP-1 was thought to exercise its role
via both a DNA-PK–dependent (26) and –independent manner
(27). Two other members of the PARP family, PARP-2 and
PARP-3, also possess poly(ADP-ribose) polymerase activity (28).
However, PARP-1 is thought to be the major contributor and
responsible for over 90% of cellular PARylation (29, 30). Thus, it
is possible that PARP-1 is the major downstream mediator of
FASN in the NHEJ repair of DSBs.
It is currently unknown how increased PARP-1 enhances Ku
recruitment to chromatin for NHEJ repair of DSBs. Recently,
it was found that PARP in Dictyostelium discoideum promotes
Ku recruitment/retention to chromatin via PARylating nuclear
proteins that bind Ku proteins at its C-terminal PAR-binding
zinc-finger (PBZ) domain (14). However, human Ku70 and
Ku80 do not possess a PBZ domain. Thus, it is unlikely that
human Ku proteins bind directly to PARylated chromatin via a
PBZ domain. APLF, also known as Xip1, is a recently discovered
DNA repair protein with two C-terminal PBZ domains, which
are required for the recruitment of APLF to sites of DNA
damage (31, 32). Interestingly, APLF is known to associate with
core NHEJ components such as XRCC4-DNA ligase IV and Ku
proteins (33–35). It is thus tempting to speculate that the aug-
mented Ku protein recruitment to chromatin by increased
PARP-1 expression in human cancer cells may be via association
with APLF that binds to the abundant PARylated chromatin via
its PBZ domain carrying Ku.
It is noteworthy that PARP-1 has also been suggested to
compete with Ku proteins in binding to DNA ends and, thus,
perhaps inhibits classical NHEJ repair activity and may con-
tribute to DSB repair via an alternative NHEJ (36). However, we
clearly showed that increased PARP-1 expression and activity
up-regulate instead of inhibit Ku protein recruitment and DNA-
PK activity. Although the reason is currently unclear for the
difference between these studies, the results from these studies
indicate that PARP-1 may contribute to NHEJ repair of DSBs
via different pathways.
Fig. 7. NF-κB and SP1 regulate PARP-1 transcription by binding to the same
site. (A) Effect of SP1 or Flag-p65 overexpression on PARP-1 expression in
MCF7 and Panc-1 cells as determined by Western blot analysis (Left) and
quantitative (q)RT-PCR (Right). (B) Effect of shRNA-induced p65 knockdown
on PARP-1 expression in MCF7 and Panc-1 cells as determined using Western
blot (Left) and qRT-PCR (Right). (C) Effect of NF-κB activation by TNF-α
treatment on PARP-1 expression in MCF7 and Panc-1 cells as determined by
Western blot and qRT-PCR analysis. (D) Competition between p65 and SP1 in
regulating PARP-1 expression. Panc-1 cells were transiently transfected with
various combinations of Flag-p65 and SP1 cDNA together with vector control
to ensure a constant total level of DNA for each transfection. Cells were
harvested at 48 h post transfection and subjected to Western blot analysis.
(E) ChIP assay. Panc-1 cells were transiently transfected with Flag-p65 cDNA
(p65) or a vector control (Vec) followed by ChIP without or with normal IgG
control or SP1 antibody and real-time PCR analysis. Data are expressed as the
percentage of signal detected with the nonimmunoprecipitated input (10%
of total chromatin). (F) Effect of shRNA-mediated p65 knockdown on NHEJ
activity in MCF7 cells (n = 3; *P < 0.05, **P < 0.01; error bars, standard
deviation).
E6970 | www.pnas.org/cgi/doi/10.1073/pnas.1609934113 Wu et al.
Our finding that FASN may reduce HR repair of DSBs via up-
regulating PARP-1 is interesting but consistent with previous
observations. Initially, PARP-1 was thought to have a protective
role against HR via binding to DNA breaks and preventing the
HR machinery from recognizing and processing DNA lesions
(37). Indeed, it was found later that inhibition or loss of PARP-1
increased HR activity in cells (38) or in vivo (39). PARP-1 may
inhibit HR activity by PARylating BRCA1 and inhibiting its
activity (40) or by inhibiting the expression of BRCA1 (41) and
BRCA2 (42). It has also been observed that overaccumulation of
PARylation also interferes with HR activity (43). Clearly, FASN
regulates both NHEJ and HR via up-regulation of PARP-1. The
promotion of the NHEJ pathway over HR may be a unique
solution adopted by FASN-overexpressing cancer cells to achieve
efficient repair of DSBs, as HR was associated with a slower rate
of repair compared with NHEJ (44, 45). Our finding suggests
that inhibiting FASN in HR-deficient cells may provide a novel
approach of eliminating cancer cells in combination with DNA-
damaging treatments or with PARP inhibitors.
Although it has been shown that the rat PARP-1 promoter is
regulated by a composite binding site for the transcription fac-
tors SP1 and NF1, we found a similar composite binding site for
SP1 and p65 in the promoter of human PARP-1. Whereas SP1
activates, p65 inhibits PARP-1 transcription by binding to the
same composite site in a mutually exclusive manner. Composite
elements are regulatory sequences commonly found in vertebrate
gene promoters (46) that contain two or more closely positioned
binding sites for distinct transcription factors and provide a way
for fine-tuning gene expression. Binding of transcription factors to
composite elements can either synergistically or antagonistically
regulate gene expression. Similar to our findings, NF-κB antago-
nizes SP1 activation of the P-selectin promoter via an NF-κB/SP1
composite site (47).
Previously, we found that FASN suppresses TNF-α produc-
tion (4), which is consistent with our current finding of reduced
NF-κB expression by FASN. However, it is unknown how FASN
inhibits NF-κB expression. Although the end product of FASN
catalysis, palmitate, may mediate FASN regulation of SP1 ex-
pression, it does not appear to affect NF-κB. Previously, we
found that supplementation of palmitate increased drug re-
sistance of breast cancer cells (2), which is consistent with the up-
regulation of SP1, which in turn increases NHEJ. Thus, lipid
metabolism may play an important role in cancer cell survival
against genotoxic insults. However, it remains to be determined
how palmitate regulates SP1 and how FASN regulates NF-κB.
We are currently working in this direction.
Experimental Procedures
All experiments involving human cell lines and recombinant DNA were ap-
proved by the Institutional Biosafety Committee at Indiana University.
Construct Engineering. A pCβA-SP1 construct was engineered for ectopic SP1
overexpression. Briefly, cDNA encoding SP1 was purchased from Open Bio-
systems and released from the vector, pOTB7, by double digestion with
EcoRI and XhoI. The cDNA fragment was inserted into the mammalian cell
expression vector, pCβA (48), digested with EcoRI and XhoI, resulting in
pCβA-SP1, and confirmed by DNA sequencing.
Cell Lines and Transient Transfections. Human breast cancer cell line MCF7 and
pancreatic cancer cell line Panc-1 were cultured at 37 °C with 5% (vol/vol) CO2
in DMEM supplemented with 10% (vol/vol) FBS, 100 units per mL penicillin,
and 100 μg/mL streptomycin. FASN-overexpressing MCF7 (M/FASN) and Panc-
1 (P/FASN) cells and their respective vector-transfected control clones
(M/Vec, P/Vec), as well as stable MCF7/AdVp3000 cells with FASN knock-
down (M3K/Sh) and its control scrambled shRNA-transfected clone (M3K/Scr)
were generated previously (2, 8) and maintained in DMEM supplemented
with 10% (vol/vol) FBS, 100 units per mL penicillin, 100 mg/mL streptomycin,
and 400 μg/mL G418.
For transient transfection of pCβA-SP1, pcDNA3-p65-flag (49), or p65
shRNA (49) constructs and their respective control plasmids, cells were
seeded at 3 × 105 cells per well in six-well plates and cultured for 24 h before
transfection with 2 μg plasmids using Metafectene Pro (Biontex) according
to the manufacturer’s instructions. For transient transfection of PARP-1
siRNA (Santa Cruz; sc-29437) or FASN siRNA (Santa Cruz; sc-43758), 6 × 105
cells were plated in six-well plates for 24 h, followed by transfection with
siRNAs using Metafectene Pro according to the supplier’s instructions. The
final siRNA concentrations for PARP-1 and FASN were 50 and 100 nM,
respectively. At 48 h after transfection, the cells were collected or seeded for
different assays.
Western Blot Analysis. Western blot analysis was performed as we previously
described (2, 4) using primary antibodies against FASN (BD Biosciences;
610962), PARP-1 (Cell Signaling; 9542), histone H3 (Cell Signaling; 2650),
NF-κB p65 (Santa Cruz; sc372), Ku70 (Santa Cruz; sc-1487), γ-H2AX (Millipore;
05636), and anti-PAR (Trevigen; 4335). Final images were captured using
FluorChem HD2 imager, and staining intensity was quantified using the
AlphaEaseFC program associated with the FluorChem HD2 imager (both
from Alpha Innotech).
Thiazolyl Blue Tetrazolium Bromide and Colony-Formation Survival Assays. A
thiazolyl blue tetrazolium bromide (MTT) survival assay was performed as
previously described (50). Briefly, cells in 96-well plates were cultured for
24 h and treated with various concentrations of doxorubicin, bleomycin,
cisplatin, or H2O2 continuously for 3 d followed by addition of MTT to a final
concentration of 0.5 mg/mL and incubation at 37 °C for 4 h. The medium was
then removed and formazan was solubilized in dimethyl sulfoxide, and the
OD570 was measured by a Synergy H1 hybrid reader (BioTek). IC50s were
obtained from the fitted curves generated by Prism 5.0 (GraphPad Soft-
ware). The relative resistance factor (RRF) was calculated using the formula
RRF = IC50(test)/IC50(control) with the control normalized as 1. For MCF7/
AdVp3000 (M3K)-derived cell lines, 10 μM fumitremorgin C (FTC) was pre-
incubated for 30 min before addition of doxorubicin to inhibit high ABCG2
activities in these cell lines. For the MTT assay following PARP-1 knockdown,
MCF7/FASN cells were transiently transfected with control scramble or PARP-1
siRNA. At 24 h after transfection, cells were replated in 96-well plates and
treated with doxorubicin for survival analysis.
The colony-formation assay was performed as previously described (51)
for ionizing radiation and UVB treatments. Briefly, 100 cells were plated in
60-mm dishes and incubated for 24 h followed by treatment with IR or UVB
and continuous culture for 10 d before removing the medium and washing
the cells with PBS. Colonies were fixed and stained with a solution con-
taining 0.05% (wt/vol) crystal violet and 20% (vol/vol) methanol in PBS.
Immunofluorescence Staining and Imaging. Immunofluorescence staining and
imaging were performed as previously described (52). Briefly, cells were
cultured on coverslips in 60-mm culture dishes and treated with IR. At dif-
ferent times following IR treatment, the cells on coverslips were washed
with PBS, fixed with 50:50 (vol/vol) acetone/methanol at room temperature
for 10 min, blocked with 1% BSA in PBS for 30 min, and probed with anti–
γ-H2AX antibody (1:100; Millipore; 05636) at room temperature for 1 h,
followed by washing and incubation with FITC-conjugated goat anti-mouse
IgG at room temperature for 30 min. The coverslips were washed again and
incubated with 4′,6-diamidine-2-phenylindole dihydrochloride (DAPI) (1 μg/mL
in PBS) for 10 min in the dark. The coverslips were then mounted on slides
before viewing with an Olympus 2 confocal microscope.
Neutral Comet Assay. The neutral comet assay was performed using a kit from
Trevigen according to the manufacturer’s instructions. Briefly, cells following
IR were harvested and mixed with low-temperature-melting agarose as
single-cell suspensions at 37 °C. The resulting cell/agarose mixture was im-
mediately layered onto CometSlides (Trevigen). The agarose was allowed to
set for 1 h at 4 °C and cells on the slides were then lysed at 4 °C for 30 min in
the dark. After lysis, the slides were subjected to electrophoresis and then
immersed twice in distilled water for 10 min and once in 70% (vol/vol)
ethanol for 5 min. The slides were then dried completely at room temperature
and stained with SYBR Green I (Trevigen). Comets were observed and recorded
by a Zeiss Axiovert 25 fluorescence microscope equipped with a Zeiss CCD
camera and analyzed with CometScore version 1.5 (TriTek). The olive tail
moment was determined by scoring 100 cells in each sample as previously
described (53).
Host Cell Reactivation Assay. The host cell reactivation NHEJ assay was per-
formed as previously described (54) with minor modifications. Briefly, 5 × 104
cells per well were seeded in 24-well plates and cultured overnight before
transfection using Lipofectamine Plus of either 400 ng intact (control) or
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HindIII-linearized (test) pGL3-encoding firefly luciferase (FL) together with
20 ng pRL-TK (Promega)–encoding renilla luciferase (RL) as a control for
transfection efficiency. Cells were harvested at 8 h following transfection,
and both FL and RL activities were determined using a Dual-Luciferase Re-
porter Assay System (Promega). FL activities from both control and test
groups were first normalized to that of RL activities before calculating NHEJ
activity using the formula NHEJ activity = (normalized FL activity in the test
group) × 100/(normalized FL activity in the control group).
The host cell reactivation HR assay was performed as previously described
(55) with modifications. Briefly, the pGL3 plasmid was digested with NcoI
and XcmI to generate a fragment containing the SV40 promoter and the 5′
portion of the FL gene as well as with BsrGI and BamHI to generate another
fragment containing the 3′ portion of the FL gene and the polyA signal.
These two DNA fragments, containing a 245-bp-overlapping region, were
purified and cotransfected along with the pRL-TK control plasmid into 7 ×
104 cells per well in a 24-well plate using Metafectene Pro transfection re-
agent. Transfections with either the NcoI-XcmI or BsrGI-BamHI fragment
alone were used as negative controls. At 24 h after transfection, cells were
harvested for the Dual-Luciferase Reporter Assay as described above. FL
activities were first normalized to RL activities for transfection efficiency
before deriving relative HR activity using the formula HR activity (fold) =
(normalized FL activity in P/FASN or M3K/Sh cells)/(normalized FL activity in
P/Vec or M3K/Scr cells).
DNA-PK Activity. DNA-PK activity was analyzed using the SignaTECT DNA-
Dependent Protein Kinase Assay System (Promega) according to the manu-
facturer’s instructions. Briefly, 10 μg nuclear extract with endogenous DNA
removed by DEAE-Sepharose filtration was incubated with biotinylated
peptide substrate, [γ-32P]ATP, and either DNA-PK activation buffer or DNA-
PK control buffer for 5 min at 30 °C. Termination buffer was added, and
10 μL of each reaction sample was spotted onto a SAM2TM biotin-capture
membrane. The SAM2TM membrane were then washed and dried before
analysis by scintillation counting. DNA-PK activity is expressed as specific
activity in pmol ATP/min per μg protein.
Real-Time Quantitative PCR Analysis. Real-time quantitative PCR analysis was
performed as previously described (4, 56). Briefly, cells were harvested, and
total RNA was extracted using an RNeasy Mini Kit (Qiagen) followed by real-
time RT-PCR using the Power SYBR Green RNA-to-CT 1-Step Kit (Applied
Biosystems). Data were normalized to an internal control gene, glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH). Primer pairs used were
5′-CCCAGGGTCTTCGGATAG-3′ (forward) and 5′-AGCGTGCTTCAGTTCATACA-3′
(reverse) for PARP-1. Amplification of a single PCR product was confirmed by
melt-curve analysis.
NF-κB Activity Assay. For the NF-κB activity assay, P/FASN, M3K/Sh, and their
control P/Vec and M3K/Scr cells were seeded at 5 × 104 cells per well in
24-well plates and transfected with a PathDetect NF-κB Cis-Reporting
plasmid (Agilent Technologies). pRL-TK–encoding renilla luciferase was
cotransfected as a control for transfection efficiency. At 48 h after trans-
fection, cells were harvested for luciferase assay using the Dual-Luciferase
Reporter Assay System as described above.
Cell-Cycle Analysis. Cells seeded in 100-mm dishes at 6 × 105 cells per dish
were cultured for 3 d before treatment and cell-cycle analysis. For serum
starvation, the cells were washed with serum-free media and cultured in the
same media for 48 h before fixation in 70% (vol/vol) ethanol at room tem-
perature for 30 min. For thymidine block, the cells were treated with 2 mM
thymidine for 28 h followed by thymidine removal and culture for 10 h in
complete media without thymidine. The cells were treated again with 2 mM
thymidine for 24 h followed by fixation with ethanol as described above. For
nocodazole treatment, cells were cultured in media containing 100 ng/mL
nocodazole for 18 h and followed by fixation with ethanol as described
above. The fixed cells were then washed with PBS, stained with 50 μg/mL
propidium iodide, and digested with 100 μg/mL RNase at 37 °C for 30 min
before analysis using a FACScan flow cytometer (BD Bioscience). Cell-cycle
distribution was analyzed with the ModFit LT program (Verity Software
House).
Chromatin Immunoprecipitation. ChIP was performed as previously described
(57) using a Millipore ChIP Assay Kit. Briefly, Panc-1 cells were seeded at 1 ×
106 in 100-mm dishes and cultured for 24 h before transfection with Flag-
p65 cDNA or vector control. At 48 h post transfection, cells were fixed with
1% formaldehyde and subjected to ChIP analysis. Primers for the PARP-1
promoter were 5′-CCGGGTCCTCCAAAGAGCTA-3′ (forward) and 5′-GCCGT-
TCCCTGATAGATTGCT-3′ (reverse). Data were analyzed as the percentage of
input of the total samples and calculated as previously described (58).
Statistical Analysis. Student’s t test was used for all statistical analysis, with
P < 0.05 considered significant. All experiments were performed indepen-
dently at least three times for statistical analysis.
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